Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.71 |
| ▸ | RBP4 | P02753 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613970 | 0.93 | SCD (0.74) | SCDRBP4TTR | |
| SCHEMBL13547456 | 0.91 | SCD (0.68) | SCDRBP4TTRCYP3A4CYP2D6 | |
| SCHEMBL3611432 | 0.86 | SCD (0.69) | SCDRBP4TTRCYP3A4CYP2D6 | |
| SCHEMBL3608227 | 0.86 | SCD (0.72) | SCDRBP4TTR | |
| SCHEMBL1819943 | 0.84 | SCD (0.54) | SCD | |
| SCHEMBL13547451 | 0.84 | SCD (0.60) | SCDCYP3A4CYP2D6 | |
| SCHEMBL3609246 | 0.84 | SCD (0.63) | SCDRBP4TTR | |
| SCHEMBL13547465 | 0.83 | SCD (0.60) | SCDRBP4TTRCYP3A4CYP2D6 | |
| SCHEMBL3599769 | 0.83 | SCD (0.60) | SCDRBP4TTRCYP3A4CYP2D6 | |
| SCHEMBL13547466 | 0.83 | SCD (0.62) | SCDRBP4TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951805-B2 | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase | XENON PHARMACEUTICALS INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | SCD, SCD5, NR1H2 | SCD 1/4885RBP4 657/4885TTR 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.